Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DNM2 | P50570 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815715 | 0.86 | MKNK1 (0.47) | KMT2ARAB9AL3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL84398 | 0.82 | ACACB (0.42) | ACACBHRH4DNM2CDC7MAPK8 | |
| SCHEMBL21797166 | 0.79 | CDC7 (0.46) | KMT2ARAB9AL3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL1800915 | 0.78 | SMN1; SMN2 (0.43) | KMT2ARAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL12411162 | 0.76 | MAPK8 (0.47) | KMT2ARAB9AACACBL3MBTL1HRH4 | |
| SCHEMBL14516259 | 0.76 | CYP1A2 (0.45) | HRH4CYP1A2CYP2C19DNM2CDC7 | |
| SCHEMBL28605998 | 0.74 | IDH1 (0.42) | ACACBHRH4DNM2CDC7MAPK8 | |
| SCHEMBL13384588 | 0.73 | HRH4 (0.52) | HRH4DNM2MAPK8MERTKHTR7 | |
| SCHEMBL91452 | 0.73 | NPSR1 (0.46) | RAB9AHRH4SMN1; SMN2DNM2CDC7 | |
| SCHEMBL16815728 | 0.72 | KMT2A (0.46) | KMT2ARAB9AL3MBTL1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619204-B1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2022-12-01 | — | — | US | disclosed |
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | THE UNIVERSITY OF MELBOURNE (AU) | 2020-03-12 | — | — | US | disclosed |
| CN-110753688-A | Compounds for the treatment of respiratory diseases | 墨尔本大学 | 2020-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | KMT2A 3310/4885RAB9A 2285/4885ACACB 245/4885 |
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | KMT2A 3310/4885RAB9A 2285/4885ACACB 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.